FDA-approved tirzepatide (Mounjaro and Zepbound) Both Mounjaro and Zepbound contain the same active ingredient, tirzepatide, manufactured by Eli Lilly
It plays a role in improving insulin sensitivity, supporting glucose utilization, and enhancing metabolic efficiency at the cellular level
The STEP 4 trial showed that stopping semaglutide leads to regaining approximately two-thirds of the lost weight within a year
Improved Inflammatory Response The anti-inflammatory properties of BPC-157 have been well-documented and observable in various tissue types, including the lungs, liver, GI tract, and brain [11, 23]
Within the clinical trial setting, retatrutide has been associated with a range of adverse effects, the majority of which are gastrointestinal in nature
Department of Health & Human Services (HHS) Secretary Robert F